查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1620699

肺炎鏈球菌疫苗市場：按類型、適應症、年齡層、分佈 - 全球預測 2025-2030

Pneumococcal Vaccine Market by Type (Conjugate Vaccines, Polysaccharide Vaccines), Indication (Bronchitis, Meningitis, Pneumonia), Age Group, Distribution - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年肺炎鏈球菌疫苗市值為107.3億美元，預計2024年將達到115.6億美元，複合年成長率為7.92%，預計到2030年將達到183億美元。

肺炎鏈球菌疫苗市場的目標是預防肺炎球菌引起的感染疾病，這對於降低所有年齡段，特別是嬰幼兒、老年人和免疫力人群的發病率和死亡率至關重要。該市場包括結合疫苗和多醣疫苗等多種類型的疫苗，主要應用於兒童、成人和特定風險族群的免疫計劃。最終用戶主要是醫療保健提供者、政府衛生部門和進行疫苗試驗的研究機構。目前，市場發展是由人們對肺炎鏈球菌感染的認知提高、政府免疫工作以及疫苗開發技術進步所推動的。值得注意的機會包括擴大免疫率低的新興經濟體的疫苗覆蓋率，以及利用疫苗技術的進步來提高針對更廣泛病毒株的覆蓋率和功效。然而，市場發展面臨開發成本高、監管指南嚴格和疫苗分配挑戰等限制，特別是在低收入地區。此外，疫苗有效性的變化和非疫苗血清型的出現也可能阻礙廣泛使用。下一代疫苗的開發有創新機會，例如口服疫苗和微針陣列，具有更廣泛的保護範圍和改進的給藥方法。此外，專注於增強針對抗藥性菌株的疫苗功效的研究和開發可以提供顯著的市場優勢。由於市場的性質，競爭非常激烈，輝瑞（Pfizer）、默克（Merck）和GlaxoSmithKline Plc）等主要參與者處於領先地位，但專注於負擔得起且易於使用的解決方案的新進入者也有空間。與公共衛生機構的合作以及對研發的投資可能會促進市場進入和擴張。因此，重要的是要跟上技術進步、監管變化和不斷變化的感染疾病模式，以利用潛在的機會並克服當前的挑戰。

主要市場統計
基準年[2023] 107.3億美元
預測年份 [2024] 115.6億美元
預測年份 [2030] 183億美元
複合年成長率（%） 7.92%

市場動態：快速發展的肺炎球菌疫苗市場的關鍵市場洞察

供需的動態交互作用正在改變肺炎球菌疫苗市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 肺炎鏈球菌疾病的盛行率增加
    • 加強對肺炎鏈球菌疫苗接種的意識提升計劃
  • 市場限制因素
    • 開發肺炎鏈球菌疫苗高成本
  • 市場機會
    • 推出新型肺炎鏈球菌疫苗，可廣泛預防各種細菌菌株
    • 完善低溫運輸網路，拓展新型配送體系發展
  • 市場挑戰
    • 疫苗生產臨床試驗的延誤

波特五力：駕馭肺炎鏈球菌疫苗市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解肺炎鏈球菌疫苗市場的外部影響

外部宏觀環境因素在塑造肺炎球菌疫苗市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助企業預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解肺炎鏈球菌疫苗市場的競爭狀況

肺炎鏈球菌疫苗市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，以應對日益激烈的競爭。

FPNV 定位矩陣肺炎鏈球菌疫苗市場供應商的績效評估

FPNV定位矩陣是評估肺炎鏈球菌疫苗市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了肺炎球菌疫苗市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，肺炎球菌疫苗市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開發：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、未開發地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 肺炎鏈球菌感染的傳播
      • 加強肺炎鏈球菌疫苗接種的認知計劃
    • 抑制因素
      • 研發肺炎鏈球菌疫苗成本高昂
    • 機會
      • 推出新型肺炎鏈球菌疫苗，針對不同菌株提供更廣泛的保護
      • 完善低溫運輸網路，拓展新型配送體系發展
    • 任務
      • 疫苗生產臨床試驗處理緩慢
  • 市場區隔分析
    • 類型：增加使用產生強烈免疫反應（包括記憶反應）的結合疫苗
    • 分發：透過政府當局擴大肺炎球菌疫苗的供應，並提高高風險族群的疫苗接種率
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 肺炎鏈球菌疫苗市場：依類型

  • 結合疫苗
  • 多醣體疫苗

第7章 肺炎鏈球菌疫苗市場適應症

  • 支氣管炎
  • 腦膜炎
  • 肺炎
  • 敗血症

第8章肺炎鏈球菌疫苗市場：依年齡層別

  • 成人
  • 嬰幼兒

第9章 肺炎鏈球菌疫苗市場經銷商

  • 政府機關
  • 非政府組織

第10章美洲肺炎鏈球菌疫苗市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太肺炎鏈球菌疫苗市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲肺炎鏈球菌疫苗市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • FDA核准默克新型肺炎鏈球菌疫苗提供廣泛保護
    • Vaxcyte 透過加強與 Lonza 在肺炎鏈球菌疫苗生產方面的合作來加強全球供應鏈
    • FDA核准輝瑞 Prevenar 20，這是預防肺炎鏈球菌感染的重大突破
  • 戰略分析和建議

公司名單

  • AstraZeneca PLC
  • Biological E. Limited
  • Biovac
  • CSL Limited
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Incepta Pharmaceuticals Ltd.
  • Lonza AG
  • Merck & Co., Inc.
  • Panacea Biotec Limited
  • Pfizer, Inc.
  • Sanofi SA
  • Serum Institute of India Pvt. Ltd.
  • Vaxcyte Inc.
  • Walvax Biotechnology Co., Ltd.
Product Code: MRR-43539E5D3200

The Pneumococcal Vaccine Market was valued at USD 10.73 billion in 2023, expected to reach USD 11.56 billion in 2024, and is projected to grow at a CAGR of 7.92%, to USD 18.30 billion by 2030.

The pneumococcal vaccine market, targeting prevention of infections caused by Streptococcus pneumoniae bacteria, is pivotal in reducing morbidity and mortality rates across all age groups, particularly among infants, the elderly, and individuals with compromised immune systems. The scope of the market encompasses various vaccine types such as conjugate and polysaccharide vaccines, with applications primarily in immunization schedules for children, adults, and specific at-risk populations. End-users are primarily healthcare providers, government health departments, and research organizations conducting vaccine trials. Currently, market growth is driven by increasing awareness of pneumococcal diseases, governmental immunization initiatives, and technological advancements in vaccine development. Notable opportunities include expanding the vaccine's reach in emerging economies with lower immunization rates and leveraging advancements in vaccine technology for broader strain coverage and enhanced efficacy. Market growth, however, faces limitations such as high development costs, stringent regulatory guidelines, and challenges in vaccine distribution logistics, particularly in low-income regions. Additionally, varying vaccine efficacy rates and the emergence of non-vaccine serotype strains could hinder widespread adoption. Innovation opportunities exist in developing next-generation vaccines with broader protective profiles and improved administration methods, such as oral vaccines or micro-needle arrays. Furthermore, research and development focusing on enhancing vaccine efficacy against resistant strains could offer significant market advantages. The market's nature is competitive with key players like Pfizer, Merck, and GlaxoSmithKline leading developments, but there is room for new entrants focusing on affordable and accessible solutions. Collaborative efforts with public health entities and investments in R&D can facilitate market entry and expansion. Consequently, staying abreast of technological advancements, regulatory changes, and shifting infectious disease patterns is crucial for leveraging potential opportunities and overcoming present challenges.

KEY MARKET STATISTICS
Base Year [2023] USD 10.73 billion
Estimated Year [2024] USD 11.56 billion
Forecast Year [2030] USD 18.30 billion
CAGR (%) 7.92%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Pneumococcal Vaccine Market

The Pneumococcal Vaccine Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of pneumococcal diseases
    • Rising awareness programs regarding the use of pneumococcal vaccination
  • Market Restraints
    • High cost associated with the development of pneumococcal vaccines
  • Market Opportunities
    • Introduction of novel pneumococcal vaccines for broader protection against various bacteria strains
    • Improving cold chain networks and growing development of novel delivery systems
  • Market Challenges
    • Slow processing of clinical trials for the production of vaccine

Porter's Five Forces: A Strategic Tool for Navigating the Pneumococcal Vaccine Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Pneumococcal Vaccine Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Pneumococcal Vaccine Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Pneumococcal Vaccine Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Pneumococcal Vaccine Market

A detailed market share analysis in the Pneumococcal Vaccine Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Pneumococcal Vaccine Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Pneumococcal Vaccine Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Pneumococcal Vaccine Market

A strategic analysis of the Pneumococcal Vaccine Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Pneumococcal Vaccine Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca PLC, Biological E. Limited, Biovac, CSL Limited, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Incepta Pharmaceuticals Ltd., Lonza AG, Merck & Co., Inc., Panacea Biotec Limited, Pfizer, Inc., Sanofi SA, Serum Institute of India Pvt. Ltd., Vaxcyte Inc., and Walvax Biotechnology Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Pneumococcal Vaccine Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Conjugate Vaccines and Polysaccharide Vaccines.
  • Based on Indication, market is studied across Bronchitis, Meningitis, Pneumonia, and Sepsis.
  • Based on Age Group, market is studied across Adults and Infants & Young Children.
  • Based on Distribution, market is studied across Government Authorities and Non-Governmental Organizations.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of pneumococcal diseases
      • 5.1.1.2. Rising awareness programs regarding the use of pneumococcal vaccination
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with the development of pneumococcal vaccines
    • 5.1.3. Opportunities
      • 5.1.3.1. Introduction of novel pneumococcal vaccines for broader protection against various bacteria strains
      • 5.1.3.2. Improving cold chain networks and growing development of novel delivery systems
    • 5.1.4. Challenges
      • 5.1.4.1. Slow processing of clinical trials for the production of vaccine
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Growing usage of conjugate vaccines to produce a strong immune response that includes a memory response
    • 5.2.2. Distribution: Growing availability of pneumococcal vaccine through government authorities for enhancing vaccination coverage among at-risk populations
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Pneumococcal Vaccine Market, by Type

  • 6.1. Introduction
  • 6.2. Conjugate Vaccines
  • 6.3. Polysaccharide Vaccines

7. Pneumococcal Vaccine Market, by Indication

  • 7.1. Introduction
  • 7.2. Bronchitis
  • 7.3. Meningitis
  • 7.4. Pneumonia
  • 7.5. Sepsis

8. Pneumococcal Vaccine Market, by Age Group

  • 8.1. Introduction
  • 8.2. Adults
  • 8.3. Infants & Young Children

9. Pneumococcal Vaccine Market, by Distribution

  • 9.1. Introduction
  • 9.2. Government Authorities
  • 9.3. Non-Governmental Organizations

10. Americas Pneumococcal Vaccine Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Pneumococcal Vaccine Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Pneumococcal Vaccine Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. FDA Approves Merck's New Pneumococcal Vaccine Targeting Broad Protection
    • 13.3.2. Vaxcyte Bolsters Global Supply Chain with Enhanced Lonza Collaboration for Pneumococcal Vaccine Production
    • 13.3.3. FDA Approves Pfizer's Prevnar 20 a Significant Advancement in Pneumococcal Disease Prevention
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AstraZeneca PLC
  • 2. Biological E. Limited
  • 3. Biovac
  • 4. CSL Limited
  • 5. F. Hoffmann-La Roche AG
  • 6. GlaxoSmithKline plc
  • 7. Incepta Pharmaceuticals Ltd.
  • 8. Lonza AG
  • 9. Merck & Co., Inc.
  • 10. Panacea Biotec Limited
  • 11. Pfizer, Inc.
  • 12. Sanofi SA
  • 13. Serum Institute of India Pvt. Ltd.
  • 14. Vaxcyte Inc.
  • 15. Walvax Biotechnology Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. PNEUMOCOCCAL VACCINE MARKET RESEARCH PROCESS
  • FIGURE 2. PNEUMOCOCCAL VACCINE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. PNEUMOCOCCAL VACCINE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. PNEUMOCOCCAL VACCINE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PNEUMOCOCCAL VACCINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PNEUMOCOCCAL VACCINE MARKET DYNAMICS
  • TABLE 7. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY POLYSACCHARIDE VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY BRONCHITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY MENINGITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PNEUMONIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY SEPSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY INFANTS & YOUNG CHILDREN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY GOVERNMENT AUTHORITIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY NON-GOVERNMENTAL ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 189. PNEUMOCOCCAL VACCINE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 190. PNEUMOCOCCAL VACCINE MARKET, FPNV POSITIONING MATRIX, 2023